Movantik
(naloxegol)ApprovedSmall molecule
Naloxegol is used to treat constipation caused by opioid pain medications. It works by blocking opioids' effects in the gut while allowing the pain relief to continue working in the brain.[2] Movantik is currently approved and in use across 6 indications[4].[1]
Movantik is one of 92 small molecule programs targeting Constipation. It is currently in Approved.
6
Indications
24
Total Trials
2
Active Trials
91
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
2
Patents
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
62 competitors in Brain Injury
#DrugCompanyPhaseTrials
1Movantik
AAveritas Pharma, Inc.
Approved
Ritalin
NovartisApproved
Namenda
AbbVieApproved
Buspar
Bristol-Myers SquibbApproved
Celexa
AbbVieApproved
Vimpat
UCBApproved
Rozerem
TakedaApproved
Exelon
NovartisApproved
Vyvanse
TakedaApproved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Constipation7 trials
Show 4 more trials
Tics2 trials
Paralysis1 trial
9 more indications
Cancer Pain1 trial
Postoperative Ileus1 trial
Non-Small Cell Lung Cancer1 trial
Gastrointestinal1 trial
Regulatory
FDA Approval Timeline[5]
Sep 16, 2014
MOVANTIK
NDA NDA204760
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Movantik drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for naloxegol. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Mu Opioid Receptor Antagonist[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- AAveritas Pharma, Inc.